A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma
Open Access
- 18 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 20 (1), 1-8
- https://doi.org/10.1186/s12885-020-6592-2
Abstract
Preoperative chemoradiotherapy (CRT) followed by surgery is the most common approach for patients with resectable esophageal cancer. Nevertheless, considerable numbers of esophageal-cancer patients undergo surgery as the first treatment. The benefit of neoadjuvant therapy might only be for patients with a pathologic complete response, so stratified research is necessary. Postoperative treatments have important roles because of the poor survival rates of patients with stage-IIB/III disease treated with resection alone. Five-year survival of patients with stage-IIB/III thoracic esophageal squamous cell carcinoma (TESCC) after surgery is 20.0–28.4%, and locoregional lymph-node metastases are the main cause of failure. Several retrospective studies have shown that postoperative radiotherapy (PORT) and postoperative chemoradiotherapy (POCRT) after radical esophagectomy for esophageal carcinoma with positive lymph-node metastases and stage-III disease can decrease locoregional recurrence and increase overall survival (OS). Using intensity-modulated RT, PORT reduces locoregional recurrence further. However, the rate of distant metastases increases to 30.7%. Hence, chemotherapy may be vital for these patients. Therefore, a prospective randomized controlled trial (RCT) is needed to evaluate the value of PORT and concurrent POCRT in comparison with surgery alone (SA) for esophageal cancer. This will be a phase-II/III RCT. The patients with pathologic stage-IIB/III esophageal squamous cell carcinoma will receive concurrent POCRT or PORT after radical esophagectomy compared with those who have SA. A total of 120 patients in each group will be recruited. POCRT patients will be 50.4 Gy concurrent with paclitaxel (135–150 mg/m2) plus cisplatin or nedaplatin (50–75 mg/m2) treatment every 28 days. Two cycles will be required for concurrent chemotherapy. The prescription dose will be 54 Gy for PORT. The primary endpoint will be disease-free survival (DFS). The secondary endpoint will be OS. Other pre-specified outcome measures will be the proportion of patients who complete treatment, toxicity, and out-of-field regional recurrence rate between PORT and POCRT. This prospective RCT will provide high-level evidence for postoperative adjuvant treatment of pathologic stage-IIB/III esophageal squamous cell carcinoma. clinicaltrials.gov (NCT02279134). Registered on October 26, 2014.Keywords
Funding Information
- Capital Fund for Health Improvement and Research (2016-2-4021)
This publication has 38 references indexed in Scilit:
- Postoperative Intensity-Modulated Radiotherapy Improved Survival in Lymph Node-Positive or Stage III Thoracic Esophageal Squamous Cell CarcinomaOncology Research and Treatment, 2015
- Adjuvant Radiation Therapy and Lymphadenectomy in Esophageal Cancer: A SEER Database AnalysisJournal of Gastrointestinal Surgery, 2013
- Does Surgery Improve Outcomes for Esophageal Squamous Cell Carcinoma? An Analysis Using the Surveillance Epidemiology and End Results Registry from 1998 to 2008Journal of the American College of Surgeons, 2012
- Survival after Adjuvant Chemoradiotherapy or Surgery Alone in Resectable Adenocarcinoma at the Gastro-Esophageal JunctionScandinavian Journal of Surgery, 2012
- Journal of Gastrointestinal Surgery, 2011
- Pattern of relapse in surgical treated patients with thoracic esophageal squamous cell carcinoma and its possible impact on target delineation for postoperative radiotherapyRadiotherapy and Oncology, 2010
- Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: Report of 549 casesInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Is extended volume external beam radiation therapy covering the anastomotic site beneficial in post-esophagectomy high risk patients?Radiotherapy and Oncology, 2004
- Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinomaThe Journal of Thoracic and Cardiovascular Surgery, 2003
- Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study.1993